FDA Approves Sacituzumab Govitecan for First-Line Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has granted approval for sacituzumab govitecan (Trodelvy) as a first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). This antibody-drug conjugate (ADC) is now approved for use both as a monotherapy for patients ineligible for PD-1 or PD-L1 inhibitors and in combination with pembrolizumab for those whose tumors express PD-L1, according to the Gilead Sciences official announcement.

Clinical Evidence for Monotherapy

The FDA’s approval for sacituzumab govitecan as a single agent follows results from the ASCENT-03 clinical trial. In this study, 558 patients who were not candidates for anti-PD-L1 therapy were randomized to receive either sacituzumab govitecan or the investigator’s choice of chemotherapy, which included paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin. Data showed a median progression-free survival (PFS) of 9.7 months for patients treated with sacituzumab govitecan compared to 6.9 months for those receiving standard chemotherapy. This represents a 38% reduction in the risk of disease progression or death, as reported by Medscape.

Combination Therapy with Pembrolizumab

For patients whose tumors express PD-L1—defined as a combined positive score (CPS) of at least 10 on the FDA-authorized PD-L1 IHC 22C3 pharmDx assay—the drug is approved in combination with pembrolizumab. Approval for this regimen was based on the ASCENT-04 trial, which enrolled 443 patients. Participants were randomized to receive either sacituzumab govitecan or chemotherapy, both administered alongside pembrolizumab every 21 days. The median PFS reached 11.2 months in the sacituzumab govitecan group versus 7.8 months in the chemotherapy group, marking a 35% reduction in the risk of progression or death.

Safety Profile and Warnings

Sacituzumab govitecan carries significant risks that clinicians and patients must monitor closely. According to the FDA drug labeling, the medication includes a boxed warning for severe diarrhea and potentially fatal neutropenia. Across both ASCENT-03 and ASCENT-04 studies, more than two-thirds of participants experienced grade 3 or higher adverse events. Common side effects reported by at least 25% of patients included:

• Nausea and vomiting
• Alopecia (hair loss)
• Fatigue
• Diarrhea
• Constipation
• Abdominal pain, rash, and headache (noted specifically in ASCENT-04)

Beyond the boxed warnings, the labeling alerts healthcare providers to the risks of infusion-related reactions, embryo-fetal toxicity, and the inhibition of the UGT1A1 liver enzyme. The recommended dosage remains 10 mg/kg administered on days 1 and 8 of each 21-day cycle.

Comparison with Existing Treatments

This approval distinguishes sacituzumab govitecan from other TROP2-directed ADCs currently on the market. While datopotamab deruxtecan is also indicated for unresectable or metastatic TNBC in the first-line setting, its use is restricted to patients who are not candidates for anti-PD-L1 therapy. Sacituzumab govitecan is now the only ADC in this class with an indication for first-line metastatic TNBC regardless of a patient’s anti-PD-L1 eligibility status. While these results show clear improvements in progression-free survival, overall survival data from both the ASCENT-03 and ASCENT-04 trials remain pending.

Key Takeaways

• Broad Indication: Sacituzumab govitecan is the first ADC approved for first-line metastatic TNBC regardless of PD-L1 status.
• Trial Performance: The drug reduced the risk of progression or death by 38% as a monotherapy and 35% in combination with pembrolizumab in their respective trials.
• Safety Monitoring: Severe diarrhea and neutropenia are the primary clinical concerns, necessitating strict adherence to the boxed warning protocols.